ArticleOncology letters2018
Primary extra-nodal diffuse large B-cell lymphoma: A prognostic analysis of 141 patients.
Article in Oncology letters, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 38 citations in OpenAlex.
- Primary Lymphomas of the Female Genital Tract: Recognizing the Rare Mimicker of Gynecologic Malignancy.Medical sciences (Basel, Switzerland) · 2026Review
- A comprehensive analysis of B symptoms reveals prognosis and heterogeneity across different sites of diffuse large B-cell lymphoma.Annals of hematology · 2025Article
- Primary lymphoma of the uterine cervix: A systematic review and integrated analysis of case reports and series.Oncology letters · 2025Article
- Benefit of consolidative radiation in patients with extranodal limited-stage diffuse large B-cell lymphoma: a multicenter retrospective study in China.Annals of hematology · 2024Article
- Primary thyroid lymphoma: a case series.Journal of medical case reports · 2024Article
- Review
- No difference in treatment outcome between patients with nodal versus extranodal diffuse large B-cell lymphoma.Journal of clinical and translational research · 2023Article
- Hysteroscopic Resection Followed by Adjuvant Radiotherapy: Report of a New Therapeutic Approach to Primary Cervical Diffuse Large B-Cell Lymphoma.International journal of environmental research and public health · 2022Article
- Complete tumor regression with exclusive Ayurvedic rasayana regimen in high-grade diffuse large B-cell lymphoma: A case report.Clinical case reports · 2022Article
- Site-Specific Survival of Extra Nodal Diffuse Large B-Cell Lymphoma and Comparison With Gastrointestinal Diffuse Large B-Cell Lymphoma.Journal of hematology · 2022Article
- Primary Diffuse Large B Cell Lymphoma of Bone: A Single-Center Experience.Journal of blood medicine · 2022Article
- Clinical Characteristics and Prognostic Factors in Primary Breast Diffuse Large B-Cell Lymphoma.Mediterranean journal of hematology and infectious diseases · 2022Article
- Frequent mutated B2M, EZH2, IRF8, and TNFRSF14 in primary bone diffuse large B-cell lymphoma reflect a GCB phenotype.Blood advances · 2021Article
- Cutaneous involvement in diffuse large B cell lymphoma at presentation: report of two rare cases and literature review.Journal of the Egyptian National Cancer Institute · 2021Review
- Clinicopathological spectrum of Diffuse Large B Cell lymphoma: a study targeting population yet unexplored in Pakistan.BMC research notes · 2021Article
- A Patient With Regressed Diffuse Large B-Cell Lymphoma and Aggressive Follicular Lymphoma.Cureus · 2021Article
- Primary pulmonary diffuse large B cell lymphoma presenting as bulky bilateral lung tumors.Annals of hematology · 2021Article
- Hematologic malignancies of the gastrointestinal luminal tract.Abdominal radiology (New York) · 2020Review
- Clinical Characteristics and Outcomes of Primary Breast Lymphoma: The Cleveland Clinic Experience.Cureus · 2020Article
- Primary colorectal diffuse large B-cell lymphoma initially presenting with pleural effusion: report of one case and review of literature.International journal of clinical and experimental pathology · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of lymphoma. Approximately 40% of DBLCL originates from extra-nodal sites, but the diversity of clinical presentations and the genetic and molecular alterations indicate that extra-nodal DLBCLs may be distinct disease entities. The aim of the present study was to highlight the various aspects of primary extra-nodal DLBCL (PE-DLBCL) based on a single center cohort. The data from 141 patients with PE-DLBCL treated at Peking Union Medical College Hospital were retrospectively evaluated. The primary extra-nodal sites involved were the gastrointestinal tract (n=42), central nervous system (CNS; n=38), breast (n=19), adrenal gland (n=15), female genital system (FGS; n=12), thyroid (n=8) and bone (n=7). The median overall survival rate was 28 months (range, 1-116). Multivariate analysis demonstrated that an International Prognostic Index (IPI) ≤2 (P=0.049), complete remission (CR) achieved following first-line therapy (P=0.001) and chemotherapy combined with rituximab (P<0.001) were positive prognostic factors. Patients with DLBCL with primary adrenal gland or female genital system (FGS) involvement exhibited a significantly higher risk of CNS recurrence (P<0.05). Rituximab treatment may have reduced the likelihood of CNS recurrence (P=0.005), whereas prophylaxis with intrathecal injection alone was not sufficient for prevention (P>0.05). In conclusion, IPI >2 and the lack of a CR following first-line therapy were independent prognostic risk factors for PE-DLBCL. Patients with primary adrenal gland or FGS involvement exhibited a higher risk of CNS relapse. Rituximab had a positive impact on the survival of patients with PE-DLBCL, also reducing the likelihood of CNS relapse.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.